Mech-Mind debuts as Hong Kong’s first ’embodied intelligence eye-brain-hand’ stock
Walking Together with Love, Passing the Torch for Four Decades – Savills Hong Kong Officially Launches New ‘Savills Volunteer Team’
Fashion Hong Kong delivers a sensory surge of urban energy
Formerra Receives 2026 Eaton Supplier Excellence Award
Kincora Announces Exploration Strategy Update: Drilling Planned Across Four Projects
SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) — Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company”…
Prof. Schroeder to advise on SCI-160 formulation development to enhance biological effect and extended effect…
– CEO Remi Barbier to Discuss Q1 2022 Clinical and Corporate Updates – – Stakeholders…
Transformative Shockwave C2 Intravascular Lithotripsy Catheter Will Soon Be Available in One of the World’s…
NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) — via InvestorWire – Silo Pharma Inc. (OTCQB:…
Exclusive License with Asahi Kasei Pharma to develop and commercialize Apraglutide in Japan includes $30…
Results anticipated in H2 2022 NEWTON, Mass., March 30, 2022 (GLOBE NEWSWIRE) — Acer Therapeutics…
VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the…
STOUGHTON, Mass., March 30, 2022 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced…
The Company also Plans on Sharing INKmune™ Patient Case Studies Boca Raton, Florida, March 30,…
Ji’an, Jiangxi, China, March 30, 2022 (GLOBE NEWSWIRE) — Universe Pharmaceuticals INC (the “Company”) (Nasdaq:…
WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company…
BOSTON, March 30, 2022 (GLOBE NEWSWIRE) — PepGen, Inc., advancing the next generation of oligonucleotide…
VYN201 demonstrated statistically significant improvement in treatment response for both endpoints at 1mg/kg and 10mg/kg doses…
Highlights: 10 subjects in cohort four intravenously dosed; RECCE® 327 at 1,000mg, indicating to be…
All enrolled patients were 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients that had…
– First therapeutic candidate for the treatment of SSc-ILD targeting both key fibrotic and inflammatory…
Confirmatory trial’s completion is expected in an accelerated timeline of four years with patient screening…
LEAMINGTON, Ontario, March 30, 2022 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray Brands” or the…
– Full Year 2021 Total Revenue Growth of 48%, and 11% in Core Business Segments,…